Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Journeytcon Dec 18, 2023 6:05pm
167 Views
Post# 35790765

RE:RE:Reovirus Target Population

RE:RE:Reovirus Target PopulationZero conspiracy on this one.  Just quoting actual findings.   Turbo cancer cells found saturated with the spike in the thin section pictures.  That's a finding.  And there's no surprise in it for a number of reasons including but limited to the Vax design inserted the SV40 (Simeon virus).  The SV40 is essentially banned from therapeutics because it is a known carcinogen.   Again not a conspiracy because the SV40 insertion is well published. These findings are relevant to ONC in the potential market growth of cancers. If you have modicum of factual information, scientific knowledge to contribute that would be awesome.  Otherwise I'll take your remarks for what they are.  
<< Previous
Bullboard Posts
Next >>